A
Asher Bio
A biotechnology company developing precisely targeted immunotherapies for cancer and other diseases using its cis-targeting platform
About Asher Bio
Asher Biotherapeutics is a biotechnology startup that operates in the medical and healthcare market, specifically in the development of innovative immunotherapies. The company's primary focus is on cis-targeting, a novel approach to immunotherapy that offers a higher level of selectivity. This means that their therapies are designed to target and engage two receptors on the same immune cell, thereby only activating the immune response when the targeted antigen is present. This approach aims to optimize efficacy and minimize toxicity, potentially improving patient outcomes.
The company's lead product, AB248, is a cis-targeted IL-2 therapy. IL-2 is a powerful mediator of the immune system, and AB248 is designed to specifically activate CD8+ effector T cells, which play a crucial role in the body's immune response. Preliminary results suggest that AB248 may offer superior anti-tumor activity compared to other IL-2 targeted therapies currently available and in clinical development.
Asher Biotherapeutics' business model revolves around the research, development, and eventual commercialization of their cis-targeted immunotherapies. The company's primary clients are likely to be healthcare providers and patients in need of more effective and less toxic cancer treatments. The company generates revenue through the development and sale of its innovative therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- South San Francisco, United States
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 64.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, YC S19, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2024 | $55M | $540M | Third Rock Ventures · RA Capital Management · Wellington Management · Bristol-Myers Squibb | ↗ |
| SERIES BOther financing | Sep 2021 | $108M | $432M | Janus Henderson Investors · Mission BioCapital · Invus · Third Rock Ventures | — |
Growth signals
Latest recorded traffic for Asher Bio is 3.4K monthly website visits, up 100% over the last three months. Asher Bio's team declined 34.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A11 investors entered at this stage
Third Rock Ventures
Invus
Boxer Capital
MBC Biolabs
Wellington Management
Janus Henderson Investors
Mission BioCapital
Alexandria Venture Investments
RA Capital Management
Marshall Wace
Logos Capital
Series B and later2 investors entered at this stage
Bristol-Myers Squibb
AstraZeneca
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Asher Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Asher Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.